Peder L. Myhre MD, PhD

@pmyhre

Professor of Cardiology @UniOslo_MED 🇳🇴 | Director @NorTrials Cardiovascular Center | @Brighamfellows alumni | Circulation On The Run podcast host @CircAHA |

Oslo, Norge

Joined June 2009

840Following

1KFollowers

Pinned

Peder L. Myhre MD, PhD Retweeted

Carolyn Lam@lamcardio · May 7

🎧 What an inspiring listen by @pmyhre on tackling heart failure—from cutting-edge HF research to biomarker-driven care, global challenges of implementing digital health, and how Norway is reshaping participation in cardiology clinical trials. emjreviews.com/cardiology/pod…

2.0K

Peder L. Myhre MD, PhD Retweeted

American College of Cardiology@ACCinTouch · Jul 17

Dr. @ankeetbhatt offers perspective on implementation science, “the scientific study of methods and strategies that facilitate the uptake of evidence-based practice and research into regular use by practitioners and policymakers." bit.ly/3oGbHeU #TransformCVCare

5.0K

Peder L. Myhre MD, PhD@pmyhre · Jul 7

Absolutely thrilled about the recent regulatory clearances of our cardiac amyloidosis (CA) detection model. This is a game-changer in early CA diagnosis—bringing speed, accuracy, and scale to a condition that’s too often missed or delayed. Proud of the impact this will have!

UUs2@us2_ai · Jul 7

🚨 Product Update: Us2.ai’s AI Echo Copilot™ is now FDA cleared + CE marked for cardiac amyloidosis detection! What makes it unique? ✅ Combines 2 complementary approaches in one platform: 1️⃣ AI pattern recognition — detects from a single A4C view, validated…

6.0K

Peder L. Myhre MD, PhD Retweeted

Andrew P. Ambrosy, MD, MPH@AndrewPAmbrosy · Jun 29

Athlete’s heart vs. cardiomyopathy—where’s the line? 🫀 This review breaks down how to distinguish physiologic remodeling from early-stage hypertrophic, dilated, or arrhythmogenic CM using imaging. A practical guide to navigating the “gray zone” (link.springer.com/article/10.100…). #HREV

373

Peder L. Myhre MD, PhD Retweeted

Andrew P. Ambrosy, MD, MPH@AndrewPAmbrosy · Jun 30

AF and HFpEF co-exist and drive CV risk. Managing AF in HFpEF requires an integrated approach—HF therapy, rhythm or rate control, and stroke prevention. There is a growing case for early rhythm control via ablation (link.springer.com/article/10.100…). #HREV @PaulaRambarat @JonPicciniSr

1.0K

Peder L. Myhre MD, PhD@pmyhre · Jun 28

This is super interesting. Low ApoM seems to be a key player in HF/CKM. I think we will learn much more about this as a potential therapeutic target the next decade…

AAndrew J Sauer MD@AndrewJSauer · Jun 26

🚨Two new JACC Advances papers drop today linking SGLT2 inhibitors ↔ apolipoprotein M (ApoM) across very different settings—ambulatory HFrEF (DEFINE-HF) and acute inflammation (LPS-sepsis & COVID-19). Let’s unpack why this kidney-liver-vascular axis matters. A 🧵 1️⃣/15

711

Peder L. Myhre MD, PhD@pmyhre · Jun 27

#GDMTworks 🇳🇴

KKristian Berge@BergeKristian · Jun 27

Marked increase in HFrEF GDMT in Norway (2016–2023), with 4× faster MRA uptake after 2021 ESC HF guidelines and ~50% reduction in HF hospitalisations since 2016. 📖 Full article: onlinelibrary.wiley.com/doi/10.1002/eh…

215

Peder L. Myhre MD, PhD Retweeted

Andrew P. Ambrosy, MD, MPH@AndrewPAmbrosy · Jun 24

Obesity drives a unique, early-onset form of HFpEF—often underdiagnosed. Yet, no guidelines recommend screening. This review outlines why systematic screening in obesity is overdue and proposes a tailored approach (link.springer.com/article/10.100…). #HREV @JLHarrington_MD @FudimMarat

2.0K

Peder L. Myhre MD, PhD Retweeted

Andrew P. Ambrosy, MD, MPH@AndrewPAmbrosy · Jun 18

DOACs may offer a safer, simpler alternative to warfarin for LVAD patients—especially with HM3. This review explores emerging data, device-specific considerations, and the need for prospective trials to guide anticoagulation for LVADs (link.springer.com/article/10.100…). #HREV @ninoskills

2.0K

Peder L. Myhre MD, PhD@pmyhre · Jun 14

We had the pleasure to host @mvaduganathan for a mini-tour of Oslo with talks for nephrologists (#NSN2025), cardiologists, grand rounds and a research seminar. A true leader in cardio-renal-metabolic disease and such a friendly guy! We are so grateful for your visit!🙏

KK.G. Jebsen Center for Cardiac Biomarkers@CRG_Norway · Jun 14

This year’s summer seminar was one for the books with world class speakers @mvaduganathan and @oyvlie talking about the interaction between heart and kidney and how to interpret clinical trials! 🙏 thank you

2.0K

Peder L. Myhre MD, PhD Retweeted

Muthu Vaduganathan@mvaduganathan · Jun 5

#CONFIDENCE 1⃣ + 1⃣ = 2⃣ Remarkably, kidney protection with combination therapy mathematically identical to what would be expected based on each monotherapy Finerenone (0.68) * Empagliflozin (0.71) Combination (Expected if Fully Additive): 0.48 Combination (Observed): 0.48

158

16.0K

Peder L. Myhre MD, PhD Retweeted

Håkon Ihle-Hansen@IhleHansen · May 22

2024 European blood pressure guidelines have sparked controversy, with their implications still unclear. We have applied these guidelines to a cohort study. Check it out @ESC_Journals @StrokeAHA_ASA @Tidsskriftet @escardio @ heart.bmj.com/content/early/…

299

Peder L. Myhre MD, PhD@pmyhre · May 20

Fantastic late breaker session at #HeartFailure2025 ‼️ 🇳🇴🇸🇪🇮🇹 doing really well on #GDMT uptake - especially after the 2021 @escardio guidelines, including improvements in outcomes 👏🏻 ⭐️⭐️⭐️ @BergeKristian @RInciardi #FelixLindberg

pmyhre's tweet image. Fantastic late breaker session at #HeartFailure2025 ‼️

🇳🇴🇸🇪🇮🇹 doing really well on #GDMT uptake - especially after the 2021 @escardio guidelines, including improvements in outcomes 👏🏻

⭐️⭐️⭐️ @BergeKristian @RInciardi #FelixLindberg

1.0K

Peder L. Myhre MD, PhD@pmyhre · May 19

New data from EMPEROR-Preserved: patients with more severe diastolic dysfunction seems to experience greater benefit from empagliflozin! Highly significant interactions

pmyhre's tweet image. New data from EMPEROR-Preserved: patients with more severe diastolic dysfunction seems to experience greater benefit from empagliflozin! Highly significant interactions

11.0K

Peder L. Myhre MD, PhD@pmyhre · May 19

Super interesting data from @safchat @scottdsolomon and #FINEARTS-HF: Consistent safety and efficacy of finerenone across the eGFR spectrum in HF, and seems more favorable with respect to safety in lower eGFR compared to spironolactone (TOPCAT)

pmyhre's tweet image. Super interesting data from @safchat @scottdsolomon and #FINEARTS-HF:

Consistent safety and efficacy of finerenone across the eGFR spectrum in HF, and seems more favorable with respect to safety in lower eGFR compared to spironolactone (TOPCAT)

3.0K

Peder L. Myhre MD, PhD@pmyhre · May 19

Data from #FINEARTS-HF supporting the efficacy of EARLY initiation of GDMT following hospitalization for HF. @ankeetbhatt 💫 To be confirmed REDEFINE-HF: clinicaltrials.gov/study/NCT06008…

pmyhre's tweet image. Data from #FINEARTS-HF supporting the efficacy of EARLY initiation of GDMT following hospitalization for HF. @ankeetbhatt 💫

To be confirmed REDEFINE-HF: clinicaltrials.gov/study/NCT06008…

3.0K

Peder L. Myhre MD, PhD Retweeted

Mehmet Birhan YILMAZ 🇹🇷@cardioceptor · May 17

Selfie after birthday party ⁦@AlexMebazaa⁩ ⁦@lamcardio⁩ ⁦@KarenSliwa⁩ ⁦@pmyhre⁩

625

Peder L. Myhre MD, PhD@pmyhre · May 17

Straight from a beautiful Norwegian national day celebration to Belgrade for @escardio #HeartFailure2025 ! Can’t wait to see all my HF friends and learn more. 📍Join us Tuesday 8.30 for a Late Braker registry presentation from 🇳🇴 @BergeKristian & 🇮🇹@RInciardi

pmyhre's tweet image. Straight from a beautiful Norwegian national day celebration to Belgrade for @escardio #HeartFailure2025 ! Can’t wait to see all my HF friends and learn more.

📍Join us Tuesday 8.30 for a Late Braker registry presentation from 🇳🇴 @BergeKristian &amp; 🇮🇹@RInciardi

1.0K

Peder L. Myhre MD, PhD@pmyhre · May 16

Very important topic. Many cases of HFpEF are simply a deficiency disorder. A deficiency of exercise!! 🏃‍♂️

AAndrew P. Ambrosy, MD, MPH@AndrewPAmbrosy · May 15

HFpEF is a growing public health burden with few proven therapies. Exercise training improves function, with modalities ranging from moderate-intensity to multi-modal and emerging options like IMT and FES. (link.springer.com/article/10.100…). @aepetersMD @JLHarrington_MD

435

Peder L. Myhre MD, PhD Retweeted

Andrew P. Ambrosy, MD, MPH@AndrewPAmbrosy · May 14

Inflammation is central to development/progression HF. This review unpacks the role of immune pathways, biomarkers like CRP/IL-6, and comorbidities like diabetes and obesity—while exploring the promise (and limits) of anti-inflammatory therapies in HF (link.springer.com/article/10.100…).

321